A Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Accelerated Phase
OBJECTIVES: I. Determine the safety of STI571 in patients with accelerated phase
Philadelphia chromosome positive (or chromosome negative and Bcr/Abl positive) chronic
myelogenous leukemia. II. Determine the rate of hematological response to this treatment in
these patients. III. Determine the improvements in symptomatic parameters with this
treatment in these patients. IV. Determine the cytogenetic response to this treatment in
these patients. V. Determine the time to treatment failure in these patients after receiving
this treatment.
OUTLINE: Patients receive oral STI571 daily. Treatment continues for at least 1 year in the
absence of disease progression or unacceptable toxicity. Patients who are considered to have
benefited may continue treatment beyond 1 year.
PROJECTED ACCRUAL: Not determined
Interventional
Primary Purpose: Treatment
Ilana Monteleone
Study Chair
Novartis Pharmaceuticals
United States: Federal Government
CDR0000068087
NCT00006052
June 2000
Name | Location |
---|---|
Novartis Pharmaceuticals Corporation | East Hanover, New Jersey 07936 |